MIC is administered as a subcutaneous injection (just under the skin) using a very small needle
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
The skin requires essential nutrients to stay hydrated, reduce fine lines, and maintain a healthy glow
What is the difference between AHK-Cu and GHK-Cu
[2] Pharmacokinetic studies demonstrate rapid systemic distribution with peak plasma levels occurring within 30-60 minutes of intramuscular injection, followed by extensive hepatic storage and enterohepatic recycling
Pregnancy Adequate and well-controlled studies have not been done in pregnant women